Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer

by Chan, Arlene, Conte, P., Petruzelka, L., Tubiana-Mathieu, N., Ganju, V., Llombart, A., Espie, M., Majois, F., Gil, M., Vaissiere, N., Villanova, G.
Published 2013